Results 271 to 280 of about 192,885 (309)
Some of the next articles are maybe not open access.
Pathogenesis of Triple-Negative Breast Cancer
Annual Review of Pathology: Mechanisms of Disease, 2022Triple-negative breast cancer (TNBC) encompasses a heterogeneous group of fundamentally different diseases with different histologic, genomic, and immunologic profiles, which are aggregated under this term because of their lack of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression.
Fatemeh Derakhshan, Jorge S Reis-Filho
exaly +3 more sources
Current Opinion in Oncology, 2008
Triple-negative breast cancer has been of great interest to oncologists because these cancers do not benefit from hormonal therapies or treatments targeted against human epidermal growth factor receptor 2 receptors. The only systemic therapy currently available is chemotherapy, and prognosis remains poor.
Gert, Stockmans +4 more
openaire +4 more sources
Triple-negative breast cancer has been of great interest to oncologists because these cancers do not benefit from hormonal therapies or treatments targeted against human epidermal growth factor receptor 2 receptors. The only systemic therapy currently available is chemotherapy, and prognosis remains poor.
Gert, Stockmans +4 more
openaire +4 more sources
Immunotherapy in Triple-Negative Breast Cancer
The Cancer Journal, 2021Abstract Triple-negative breast cancer (TNBC) is an aggressive subtype of mammary carcinoma. A subset of TNBC is immune activated, suggesting that immunotherapy may be a viable treatment strategy. Phase III clinical trials have shown that atezolizumab or pembrolizumab is well-tolerated in combination with chemotherapy, with progression-free ...
openaire +2 more sources
An overview of triple-negative breast cancer
Archives of Gynecology and Obstetrics, 2015Triple-negative breast cancer (TNBC) is a heterogeneous group of tumors comprising various breast cancers simply defined by the absence of estrogen receptor, progesterone receptor and overexpression of human epidermal growth factor receptor 2 gene.
Pankaj Kumar, Rupali Aggarwal
openaire +2 more sources
Metastatic Triple-negative Breast Cancer
Clinical Oncology, 2011The triple-negative class (oestrogen receptor-negative, progesterone receptor-negative and human epidermal growth factor receptor 2 [HER2]-negative) comprises about 15% of breast cancer. It is associated with a poor prognosis compared with tumours that are positive for hormone receptors or HER2.
E A, Rakha, S, Chan
openaire +2 more sources
Pathology of triple negative breast cancer
Seminars in Cancer Biology, 2021Triple negative breast cancer (TNBC) is a subtype of breast tumor lacking hormone receptors expression and HER2 gene amplification and represents 24 % of newly diagnosed breast neoplasms. In this review, pathological aspects of triple-negative breast cancer are illustrated, with particular attention to the seminal studies that defined this subtype of ...
Filippo, Borri, Annarita, Granaglia
openaire +2 more sources
Epidemiology of triple negative breast cancers [PDF]
Breast Disease, 2011 Triple negative (TN) breast cancers fail to express the three most common breast cancer receptors; i.e., estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2). Accumulating data demonstrate that epidemiological risk factor profiles also vary between TN (ER-PR-HER2-) and other breast cancers, especially ...
Gretchen L, Gierach +2 more
openaire +2 more sources
Local Treatment of Triple-Negative Breast Cancer
The Cancer Journal, 2021Abstract Triple-negative breast cancer, compared with other molecular subtypes, poses particular challenges for optimizing the timing and the extent of locoregional treatments. In the past, the combination of increased rates of both locoregional and distant recurrences led to a preference of radical surgery and extensive radiation therapy ...
Machiels, Melanie +3 more
openaire +3 more sources